[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 1 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
Page 1 of 44  [LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.    
 
 
Feasibility Study of a Bronchoscopic Ultrasound -Guided Tissue 
Acquisition System with Real -time Visualization for Collection of Cytology 
Specimens of Peripheral Pulmonary Lesions  
 
iNod Feasibility  
 
CLINICAL PROTOCOL  
 
PDM# [ADDRESS_1148037] # E7113  
 
 
Sponsored By  
[CONTACT_5708] 
[ADDRESS_1148038] 
Marlborough, MA [ZIP_CODE] -1234 
[LOCATION_003]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 This protocol contains confidential information for use by [CONTACT_113627]. The protocol should be 
held confidential and maintained in a secure location.  
Do not copy or distribute without written permission from [LOCATION_011] S cientific Corporation.  
THESE DOCUMENTS ARE THE PROPERTY OF BOSTON SCIENTIFIC CORPORATION AND SHALL NOT BE REPRODUCED, 
DISTRIBUTED, DISCLOSED OR USED FOR MANUFACTURE OR SALE OF APPARATUS WITHOUT THE EXPRESS WRITTEN 
CONSENT OF BOSTON SCIENTIFIC CORPORATION.  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page2 of [ADDRESS_1148039]  
Marlborough, MA [ZIP_CODE] 
[EMAIL_15746]  
Coordinating Principal 
Investigators  Alex Chen, MD  
Co-lead Investigator  
Washington University School of Medicine 
St. Louis, Missouri  
 
Lonny Yarmus, DO 
Co-Lead Investigator  
Johns Hopkins University 
Baltimore, Maryland  
 
Original Release: March 14, 2016  
Current Version: March 14, 2016  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 3 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
Page 3 of 44  [LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.   
 Protocol Synopsis  
 
Feasibility Study of a Bronchoscopic Ultrasound -Guided Tissue 
Acquisition System with Real -time Visualization for Collection of Cytology 
Specimens of Peripheral Pulmonary Lesions  
Objective(s)  To demonstrate feasibility to access, visualize, and obtain specimens 
adequate for cytology of lung lesions in subjects with suspected lung 
cancer when using the iNod System.  
Planned 
Indication(s) for 
Use The iNod System is intended for use for diagnostic ultrasound imaging 
and ultrasound -guided fine needle aspi[INVESTIGATOR_1516] (FNA) of extramural and 
submucosal lesions of the tracheobronchial tree.  
Test Device  The iNod System, is comprised of the following componen ts: 
• iNod Ultrasound Imaging  System  
• iNod Ultrasound  Catheter  
• iNod Biopsy  Needle  
• iNod Motor Drive  Unit 
• iNod  Sled 
 
The iNod Biopsy Needle and the iNod Ultrasound Catheter are intended 
to be used, in combination, in the Olympus BF -P190 or Olympus BF - 
MP160 Bronchoscopes.  
Study Design  Multi -center, Prospective, Single -arm Feasibility Study with Salvage.  
Number of 
Subjects  5 to 10 Subjects at a study center  
15 to 30 Subjects, across all study centers  
Number of 
Centers / 
Countries  2-3 US Study Centers  
Primary 
Endpoint  Clinical success is defined as the iNod System’s ability to acquire 
adequate specimens of cellular matter suitable for the cytologic 
evaluation of targeted lung lesions, under real -time visualization.  
Salvage Procedure: In case of primary endpoint failure with the iNod 
System, Radial EBUS -guided diagnostic sampling maneuvers (current  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148040] -of-care) will be performed in an attempt to access, visualize, and  
sample targeted lung lesions.  
Secondary 
Endpoints  1. Occurrence and severity of Adverse Events related to the iNod System 
biopsy procedures, as well as Adverse Events related to any 
subsequent Radial EBUS -guided salvage  procedures.  
2. Proportion of lesions visualized during iNod  Maneuvers  
3. Proportion of lesions accessed where iNod Biopsy Needles were 
deployed in the target lesion during study  maneuvers  
4. Proportion of iNod maneuvers that acquire specimens of cellular 
matter for  cytology  
Study Visit 
Schedule  Baseline Visit: Informed Consent, Medical History, including collection 
of a Chest CT image within 6 weeks of study procedure, which confirms 
the presence of peripheral pulmonary lesion(s).  
 
Bronchoscopy Procedure: iNod sampling of les ion followed by [CONTACT_827418] (salvage) procedures, should collected specimens be 
determined as inadequate for cytologic evaluation. Intra -procedural 
specimens collected for cytology will be documented.  
 
Completion / End of Study:  
• Following the bronchoscopic procedure, and per standard clinical 
practice, the subject will have a post -procedure chest  x-ray. 
• The subject will have a Day [ADDRESS_1148041] -Procedure Safety Call to check 
for any delayed -onset Device/Procedure/Anesthesia -related safet y 
events.  
Study Duration  The study will close after enrollment is completed. The enrollment 
period is estimated to be open for approximately [ADDRESS_1148042] Patient 
In (FPI) through Last Patient Out (LPO). Follow -up of unforeseen 
procedure -related safet y events could extend LPO beyond the date of the 
last study  procedure.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148043] (obtained within 6 
weeks) with the intention to undergo a clinically indicated 
bronchoscopic evaluation under routine clinical care. If the lesi on is 
partially solid (i.e. there is a ground glass component) then the solid 
portion must make up 80% of the  lesion.  
4. Subject for whom the decision to pursue biopsy has been made by [CONTACT_827419].  
Key Exclusion 
Criteria 1. Subjects with pure ground glass opacity, a subsolid target lesion, 
and/or a ground glass opacity identified on Chest  CT. 
2. Subjects with lesions that include endobronchial involvement, per 
Chest  CT. 
3. Subjects who lack fitness to undergo flexible bronchoscopy and 
standard of care Radial EBUS -guided cytological assessment 
evaluations, as determined by [CONTACT_11168].  
4. Subjects with known  coagulopathy.  
5. Subjects who are pregnant or nursing  mothers.  
6. Subjec ts who are currently enrolled in another investigational study 
that would directly interfere with the current study, without prior 
written approval from the  sponsor.  
Statistical Methods  
Primary 
Statistical 
Hypothesis  There will be no formal statistical hypothesis tested since this is an 
observational feasibility study documenting the first human use of the 
iNod System.  
Statistical Test 
Method  Descriptive statistics will be presented to characterize the trial data and 
describe the trial results.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 6 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
Page 6 of 44  [LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.   
 Feasibility Study of a Bronchoscopic Ultrasound -Guided Tissue 
Acquisition System with Real -time Visualization for Collectio n of Cytology 
Specimens of Peripheral Pulmonary Lesions  
Sample Size 
Parameters  Since no formal hypothesis will be tested, there is no statistical 
justification of sample size.  
Peripheral pulmonary lesions vary in their location in the 
tracheobronchial tree, their size, and their characteristics (e.g., concentric 
vs. eccentric). A sample size of 5 -10 subjects per site allows greater 
potential to evaluate the usability and perform ance of the system for 
visualization and sampling this range of lesions.  
Performance feedback for this traditional feasibility study is sought from 
more than 1 physician. While staying within the sample size confines of a 
traditional feasibility study, Bos ton Scientific has elected to seek the 
expertise of 2 to 3 interventional bronchoscopi[INVESTIGATOR_11437].  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148044]  ACCOUNTABILITY  ................................ ................................ ................................ .....................  17 
7.1. Point  of Enrollment  ................................ ................................ ................................  17 
7.2. Withdrawal  ................................ ................................ ................................ .............  17 
7.3. Enrollment  Controls  ................................ ................................ ..............................  18 
8. STUDY  METHODS  ................................ ................................ ................................ ................................ ..........  18 
8.1. Data  Collection  ................................ ................................ ................................ ....... 18 
8.2. Study  Candidate  Screening  ................................ ................................ ...................  20 
8.3. Informed  Consent  ................................ ................................ ................................ ... 20 
8.4. Baseline ................................ ................................ ................................ ....................  20 
8.5. iNod  Diagnostic  Procedure  ................................ ................................ ....................  20 
8.6. Salvage  Procedure  ................................ ................................ ................................ .. 22 
8.7. Study  Completion  ................................ ................................ ................................ ... 22 
8.8. Source  Documents  ................................ ................................ ................................ .. 22 
9. STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................ .............  23 
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 8 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
Page 8 of 44  [LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.   
 9.1. Endpoints  ................................ ................................ ................................ ................  23 
9.1.1.  Primary  Endpoint  ................................ ................................ ......................  23 
Hypotheses  ................................ ................................ ................................  23 
Sample  Size ................................ ................................ ...............................  23 
Statistical  Methods  ................................ ................................ ....................  24 
9.2. General  Statistical  Methods  ................................ ................................ ..................  24 
9.2.1.  Analysis  Sets ................................ ................................ ..............................  24 
Intent -to-Treat  Cohort  ................................ ................................ ..............  24 
Per Protocol  Cohort  ................................ ................................ ..................  24 
9.2.2.  Control of  Systematic  Error/Bias  ................................ ..............................  24 
9.2.3.  Number of Subjects per  Investigative  Site ................................ .................  24 
9.3. Data  Analyses  ................................ ................................ ................................ .........  24 
9.3.1.  Interim  Analyses  ................................ ................................ ........................  25 
9.3.2.  Subgroup  Analyses  ................................ ................................ .....................  25 
9.3.3.  Justification  of Pooling  ................................ ................................ ..............  25 
9.3.4.  Changes to  Planned  Analyses  ................................ ................................ .... 25 
10. DATA  MANAGEMENT  ................................ ................................ ................................ ................................ .. 25 
10.1. Data Collection, Processing,  and Review  ................................ .............................  25 
10.2. Data  Retention  ................................ ................................ ................................ ........  26 
11. AMENDMENTS  ................................ ................................ ................................ ................................ ................  26 
12. DEVIATIONS  ................................ ................................ ................................ ................................ ....................  26 
13. DEVICE /EQUIPMENT  ACCOUNTABILITY  ................................ ................................ .............................  [ADDRESS_1148045]  ................................ ................................ ....................  30 
14.4. Sponsor  Responsibilities  ................................ ................................ ........................  30 
14.4.1.  Role of [LOCATION_011]  Scientific  Representatives  ................................ ..................  31 
14.5. Insurance  ................................ ................................ ................................ .................  31 
15. MONITORING  ................................ ................................ ................................ ................................ ..................  31 
16. POTENTIAL RISKS  AND  BENEFITS  ................................ ................................ ................................ ..........  32 
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 9 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
Page 9 of 44  [LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.   
 16.1. Anticipated Device -related & Procedure -related  Adverse  Events  ....................  32 
16.2. Risks Associated with the  Study  Device(s)  ................................ ...........................  33 
16.3. Risks associated with Participation in the  Clinical  Study  ................................ .. 33 
16.4. Risk  Minimization  Actions  ................................ ................................ ....................  33 
16.5. Anticipated  Benefits  ................................ ................................ ...............................  33 
16.6. Risk to  Benefit  Rationale  ................................ ................................ .......................  33 
17. SAFETY  REPORTING  ................................ ................................ ................................ ................................ .... 34 
17.1. Reportable Events by [CONTACT_827420]  .........................  34 
17.2. Relationship to  Study  Device(s)  ................................ ................................ ............  36 
17.3. Investigator  Reporting  Requirements  ................................ ................................ .. 36 
17.4. [LOCATION_011] Scientific  Device  Deficiencies  ................................ ................................ .... 37 
17.5. Reporting to Regulatory Authorities / IRBs / ECs  / Investigators  .....................  38 
18. INFORMED  CONSENT  ................................ ................................ ................................ ................................ ... 38 
19. SAFETY  MONITORING  PROCESS  ................................ ................................ ................................ .............  39 
20. SUSPENSION  OR TERMINATION  ................................ ................................ ................................ ...............  40 
20.1. Premature Termination of  the Study  ................................ ................................ .... 40 
20.1.1.  Criteria for Premature Termination of  the Study  ................................ .........  40 
20.2. Termination of Study Participation by [CONTACT_5717]/  
EC Approval  ................................ ................................ ................................ ...........  [ADDRESS_1148046]  Follow -up ................................ . 40 
20.4 Criteria for Suspending/Terminating a  Study  Center  ................................ ........  41 
21. PUBLICATION  POLICY  ................................ ................................ ................................ ................................ . 41 
22. BIBLIOGRAPHY  ................................ ................................ ................................ ................................ ..............  42 
23.2.  Definitions  ................................ ................................ ................................ ...............  44 
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical P rotocol  
91122035 Rev/Ver AA  
Page 10 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 10 of 44   
 Table of Tables  
Table 6.1 -1: Inclusion  Criteria  ................................ ................................ ................................  16 
Table 6.2 -1: Exclusion  Criteria  ................................ ................................ ...............................  17 
Table 8.1 -1: Data  Collection  Schedule  ................................ ................................ ...................  19 
Table 8.8 -1: Source  Documentation  Requirements  ................................ ..............................  223 
Table 17.1 -1: Safety  Reporting  Definitions  ................................ ................................ ............  34 
Table 17.2 -1: Criteria for Assessing Relationship of S tudy Device to  Adverse  Event  ..........  36 
Table 17.3 -1: Investigator  Reporting  Requirements  ................................ ...............................  36 
Table  23.1-1: Abbreviations  ................................ ................................ ................................ ... 43 
Table  23.2-1: Definitions  ................................ ................................ ................................ ........  44 
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148047] of practice radial endobronchial 
ultrasound (R -EBUS) transbronchial needle aspi[INVESTIGATOR_1516] (TBNA) is visual izing a peripheral 
lesion on R -EBUS, locking the placement of the access sheath, removing the ultrasound 
catheter from the access sheath and then blindly advancing a sampling device to acquire 
cellular matter for cytologic evaluation. The iNod system perfo rms the same procedure with 
one fewer device exchange. It provides real -time visualization of the biopsy needle and target 
peripheral pulmonary lesions during tissue acquisition. The ultrasound probe is not retracted 
in advance of the sampling maneuver and  the sampling is completed under direct 
visualization. Compared to current standard of care methods for transbronchial sampling of 
pulmonary lesions, this approach is not expected to add additional risk. Tissue sampling 
under real -time visualization may im prove the efficiency of tissue sampling.  
Lung cancer is the most common cancer worldwide; accounting for 1.8 million new cases 
and 1.6 million deaths in 2012.1 Lung CA is also the leading cancer killer in both men and 
women in the [LOCATION_002].2 The numbe r of deaths caused by [CONTACT_827421] 3.5 percent between 1999 and 2012 from 152,156 to 157,499. In 2012, there 
were 86,740 deaths due to lung cancer in men and 70,759 in women.2 The five year survival 
rate for lung cancer is 54 per cent for cases detected when the disease is still within the lungs. 
However, only 15 percent of lung cancer cases are diagnosed at an early stage. For distant 
tumors (spread to other organs) the five -year survival rate is only 4%.[ADDRESS_1148048] X -Ray (CXR) or Computed Tomography (CT) 
scan.[ADDRESS_1148049] 
scan, the number of nodules detected requiring follow up is likely to increase exponentially 
as 25% of those screened had a detected lung abnormality.5 In studies of incidentally 
detected nodules, the prevalence of malignancy ranges from 2 -82% 6. The problem for 
clinicians is deciding on the management and further diagnostic modalities to  pursue.  
The various recommended procedures for obtaining tissue diagnosis in these intermediate 
cases i nclude transthoracic needle aspi[INVESTIGATOR_1516] (TTNA), surgery, and flexible bronchoscopy 
(FB). The diagnostic yield with FB varies with lesion size and location. A lesion having a 
bronchus sign (the finding of a CT -visible bronchus leading to the lesion) increase s the 
success of transbronchial biopsy and brushing.7_ENREF_7  The ACCP recommends that 
nodules without a CT -bronchus sign should be pursued with TTNA unless radial 
endobronchial ultrasound (R -EBUS) is available.8_ENREF_6  Bronchoscopy is commonly 
used for p ulmonary masses, but the yield, while high, does not approach 100%.  
Endobronchial ultrasound (EBUS) and radial EBUS (R -EBUS) are known to be safe and 
effective imaging techniques for transbronchial and endobronchial biopsy.9, 10 The location of 
the bronchoscope at the lesion can be verified with real -time visualization with the guide 
sheath acting as an extended working channel to maintain the location during R -EBUS  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148050] scans has led to the increased detection of pulmonary 
lesions and nodules.  
The intent of this clinical study is to demonstrate feasibility to visualize, access, and obtain 
specimens adequate for cytology of lung lesion s in subjects with suspected lung cancer when 
using the iNod System.  
 
2. Device  Description  
 
The iNod system enables real -time visualization and biopsy of peripheral pulmonary lesions 
by [CONTACT_827422]. Intended 
conditions of use are within a pulmonary endoscopy suite or a surgical suite. The iNod 
System consists of three components (and accessories) that are either identical to or slightly 
different in design to existing commercially available devices:  
• The iNod Biopsy Needle is a modified design of the commercially available [ADDRESS_1148051] Slimline Endoscopic Ultrasound Aspi[INVESTIGATOR_173234]. The modifications are 
limited to a modification of the sheath and the addition of a “needle stroke limiter” to th e 
handle. The needle and stylet within the sheath, as well as the handle, remain  unchanged.  
• The iNod Ultrasound Catheter is a slightly modified design of the commercially 
available BSC OptiCross Coronary Imaging Catheter. The modifications are limited to 
the absence of the distal guide catheter tip beyond the ultrasound transducer and the 
absence of a hydrophilic coating on the sheath.  
• The iNod Ultrasound Imaging System and its two accessories, the iNod Motor Drive 
Unit and the iNod Sled , are identical to the commercially available BSC iLab Ultrasound 
Imaging System and its  accessories.  
The study system is not approved for co mmercial use. Local IRB (Institutional Review 
Board) approval will be obtained at each participating center.  
All components of the iNod System are labeled as investigational and include information 
not limited to name [CONTACT_5758], device name [CONTACT_827440], lot number, 
expi[INVESTIGATOR_5687].  
 
2.1. Biopsy  Needle  
 
The design of the iNod Biopsy Needle is based on the commercially available [LOCATION_011] 
Scientific [ADDRESS_1148052] Slimline Endoscopic Ultrasound Aspi[INVESTIGATOR_1516] (EUS -FNA) 
Needle (K133312, cleared January 3, 2014), with modifications to allow simultaneous 
use with t he iNod Ultrasound Catheter. The modifications are limited to a modification of 
the sheath (replacing the single extrusion sheath with a multi -component single -lumen 
exterior tube) and the addition of a “needle stroke limiter” to the handle. The remainder 
of the Expect Slimline EUS -FNA Needle design, including the needle, stylet, and handle, 
is unchanged.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 13 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 13 of 44   
 The iNod Biopsy Needle is a 103 cm long (nominal) needle that can be inserted into the 
working channel of bronchoscope. It is used for fine needle aspi[INVESTIGATOR_827405]. The iNod Biopsy Needle consists of a handle assembly and a 
sheath -covered needle in a single lumen of sufficient diameter to simultaneously 
accommodate the needle/stylet assembly and the iNod Ultrasound Catheter. The needle 
has echogenic features at the distal end to facilitate real time visualization of the  device 
under ultrasound. At the proximal end of the sheath, a Y -port with a Tuohy Borst valve 
allows the iNod Ultrasound Catheter to be inserted into the lumen parallel to the needle. 
The handle assembly on the proximal end of the device is used to actuat e the needle in 
order to gather specimens. The “needle stroke limiter” on the handle limits the needle 
extension length to a maximum of 2.[ADDRESS_1148053] Slimline EUS -FNA Needle upon which it is based 
that will not be utilized in this study (e.g. sheath and adjustment knob and lock).  
 
2.2. iNod Ultrasound  Catheter  
 
The iNod Ultrasound Catheter is a modified design  of the OptiCross 40 MHz Coronary 
Imaging Catheter (K123621, cleared April 15, 2013). The changes to the design are 
limited to the absence of the distal guide catheter tip beyond the ultrasound transducer 
and the absence of the hydrophilic coating applied to the shaft of the OptiCross device  
 
The distal guide catheter tip is not necessary for the pulmonary procedure, as a guidewire 
is not required or used for access, and its presence would limit the depth to which the 
Ultrasound Catheter could access the tr acheobronchial tree. The resulting open distal end 
does allow flushing saline to empty faster, leading to more frequent replenishment of the 
flushing saline via the attached [ADDRESS_1148054] during the  procedure (3 mL) is well below that anticipated to be left 
behind in the course of a bronchoalveolar lavage (BAL) procedure (30 mL or more), 
which is recognized as safe.[ADDRESS_1148055] tracking through tortuous anatomy.  
Both the distal guide catheter tip and the hydrophilic coating are applied during the 
manufacturing process, and their absence does not alter the remaining materials of the 
device.  
 
The Cath eter body comprises a proximal telescopi[INVESTIGATOR_827406] a distal shaft. The 
proximal telescopi[INVESTIGATOR_827407] (135 
cm). The proximal telescopi[INVESTIGATOR_827408]. The distal shaft 
serves  as a flexible and acoustically transparent imaging window. The proximal 
telescopi[INVESTIGATOR_827409] a 
lumen to the imaging core. The telescope assembly allows the imaging core to  be 
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148056] cable that 
houses a pi[INVESTIGATOR_75523] (PZT) transducer at the distal imaging window. The hub assembly  
(1) provides an electro -mechanical interface between the catheter and the motor driv e 
unit and (2) incorporates a one -way check valve that is used to flush the interior of the 
catheter body. The catheter must be flushed with saline prior to use, as this provides the 
acoustic coupling media required for ultrasonic imaging.  
 
The drive cable  and PZT transducer rotate independently of the sheath assembly to 
provide 360° image resolution. The transducer converts electrical impulses sent by [CONTACT_827423]. Reflected ultrasound signals are 
converted back to el ectrical impulses, returned to the motor drive unit, and are ultimately 
processed by [CONTACT_827424].  
 
2.3. iNod Ultrasound Imaging  System  
 
The iNod Ultrasound Imaging System consists of two compact PC units (one for Image 
Processing and one for Data Acquisition), a control panel, and a monitor, installed on a 
cart. The Data Acquisition PC (front -end PC) contains a PCI -based acquisition board that 
digitizes the RF Ultrasound echo, performs front -end digital signal processing,  and direct 
memory accesses ultrasound frames in vector -based format onto the PCI bus. Once data 
is saved into host memory, the vector -based frame of data is packetized and sent over a 
private Local Area Network (LAN) connection onto the Image Processing P C (back -end 
PC) subsystem.  
 
The Image Processing PC unit represents the back -end image -processing engine. The 
real-time vector data retrieved from the Data Acquisition PC is unpacked, temporal 
filtering is executed to reduce transient matters in the frame,  and the frame data is 
converted from vector -based to raster -based frame, which can then be displayed on the 
monitor.  
 
While the real -time frames are being processed and displayed, the host processor of the 
Image Processing PC streams raw acquired data and system information onto the system 
hard drive. This stored raw data may later be converted to DICOM format to be expor ted 
to external media such as CD -Rs, DVD+Rs, removable hard disk cartridge, and DICOM 
network server.  
 
Acquisition, image processing, display, and storage are managed via a graphical user 
interface -based (GUI) Control panel touch screen, all the same as th e iLab Ultrasound 
Imaging System. The USB -based Control panel touch screen presents a series of 
software -controlled screens that manage the current imaging case in a structured 
workflow. The system interfaces with the iNod Motor Drive Unit (MDU), the iNod Sled, 
and the iNod Ultrasound Catheter. Accessories of the imaging system are as follow:  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 15 of 44  
Released 91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 15 of 44   
 iNod MDU : The iNod Motor Drive Unit is a non -sterile accessory used with the iNod 
Ultrasound Imaging System. The iNod Motor Drive Unit (MDU) is identical to the 
commercially available MDU5 PLUS for the iLab Ultrasound Imaging System. The 
MDU provides the electro -mechanics for the rotating parts of the iNod Ultrasound 
Catheter, and the interface between the Catheter and the main console.  
 
iNod Sled : The iNod Sled is a non -sterile accessory used with the iNod Ultrasound 
Imaging System. The iNod Sled is identical to the commercially available Permanent 
Sled for the iLab Ultrasound Imaging System. The iNod Sled consists of a cup that 
holds the iNod Mot or Drive Unit (MDU). The sled cup can be freely moved manually 
in a proximal or distal direction over a 10cm travel distance. When the MDU is 
placed in to the sled cup, the motordrive engages with the sled drive cone. The 
motordrive can control the movemen t of the sled cup, but this functionality is not 
intended to be used in the clinical  investigation.  
 
2.4. Medical Equipment  Description  
 
In addition to the iNod System, all pulmonary endoscopy, or surgical suites where the 
study procedure is being performed mus t also be equipped with:  
• 2.0 mm working channel bronchial scope model numbers Olympus  BF-P190 
or Olympus BF -MP160F  
• Fluoroscopy  
• All equipment necessary for Radial EBUS -guided biopsy of peripheral 
pulmonary  lesions.  
• Cytological Rapid On -Site Evaluation  (ROSE)  
All research centers are also required to have on -site capabilities for Chest X -Ray. 
 
3. Objectives  
 
To demonstrate feasibility to access, visualize, and obtain specimens adequate for cytology 
of lung lesions in subjects with suspected lung cancer when using the iNod System.  
 
4. Endpoints 
Primary  Endpoint:  
Clinical success is defined as the iNod System’s abi lity to acquire adequate specimens of 
cellular matter suitable for the cytologic evaluation of targeted lung lesions, under real -time 
visualization.  
Salvage Procedure: In case of primary endpoint failure with the iNod System, Radial EBUS  
-guided diagnostic  sampling maneuvers (current standard -of-care) will be performed in an 
attempt to access, visualize, and sample targeted lung lesions.  
Secondary Endpoints:  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 16 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 16 of 44   
 1) Occurrence and severity of Adverse Events related to the iNod System biopsy 
procedures, as well as Adverse Events related to any subsequent Radial EBUS -guided 
salvage  procedures.  
2) Proportion of lesions visualized during iNod  Maneuvers  
3) Proportion of lesions accessed where iNod Biopsy Needles were deployed during study 
maneuvers  
4) Proportion of iNod maneuvers that acquire specimens of cellular matter for  cytology  
 
5. Design, Scale, and  Duration  
 
This study is a multi -center, prospective, single -arm human feasibility assessment.  
Treatment of [ADDRESS_1148057]  Selection  
 
6.1 Inclusion Criteria  
 
Subjects who meet all of the following criteria (see  Table 6 .1-1) may be given 
consideration for inclusion in this clinical investigation, provided no exclusion criterion 
(see Section 6.2) is met.  
Table 6.1 -1: Inclusion Criteria  
1) Subject is age 18 years or  older.  
2) Subject is willing and able to comply with study procedures and provide 
written informe d consent to participate in  study.  
3) Subject with a predominantly solid lung lesion, [ADDRESS_1148058] (obtained within 6 weeks) with the 
intention to undergo a clinically indicated bronchoscopic evaluation under 
routine clinical care. If the lesi on is partially solid (i.e. there is a ground 
glass component) then the solid portion must make up 80% of the  lesion.  
4) Subject for whom the decision to pursue biopsy has been made by [CONTACT_827419].  Clinical 
Inclusi on 
Criteria  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 17 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 17 of 44   
 6.2.Exclusion Criteria  
 
Subjects who meet any one of the following crite ria (Table 6.2 -1) will be excluded from 
this clinical stud y. 
Table 6.2 -1: Exclusion Criteria  
 
7. Subject  Accountability  
 
7.1. Point of  Enrollment  
 
Point of enrollment is the time at which, following recruitment, a subject signs and dates 
the informed consent form.  
 
7.2. Withdrawal  
 
All subjects enrolled in the clinical study (including those withdrawn from the clinical 
study or lost to follow -up) shall be accounted for and documented. If a subject withdraws 
from the clinical investigation, the reason(s) shall be reported. If such wit hdrawal is due 
to problems related to investigational device safety or performance, the investigator shall 
ask for the subject’s permission to follow his/her status/condition outside of the clinical 
study.  
Reasons for withdrawal include physician discretio n, subject choice to withdraw consent, 
loss to follow -up and death. Subjects may withdraw from the study at any time, with or 
without reason, and without prejudice to further treatment. All applicable case report 
forms up to the point of subject withdrawal  must be completed. Additional data may no 
longer be collected after the point at which a subject has been withdrawn from the study 
or withdraws his/her consent, for whatever reason. All open adverse events should be  1) Subjects with pure ground glass opacity, a subsolid target lesion, and/or a 
ground glass opacity identified on Chest  CT. 
2) Subjects with lesions that include endobronchial involvement, per Chest 
CT. 
3) Subjects who lack fitness to undergo flexible bronchoscopy and standard 
of care Radial EBUS -guided cytological assessment evaluations, as 
determined by [CONTACT_11168].  
4) Subjects with known  coagulopathy.  
5) Subjects who are pregnant or nursing  mothers.  
6) Subjec ts who are currently enrolled in another investigational study that 
would directly interfere with the current study, without prior written 
approval from the  sponsor.  Clinical 
Exclusion 
Criteria  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148059] a center’s [ADDRESS_1148060] limit.  
 
7.3. Enrollment  Controls  
 
The risk of over -enrollment is minimized by [CONTACT_14662] a limited number of clinical centers 
and maintaining close communication with study centers.  
8. Study  Methods  
 
8.1. Data  Collection  
 
 Confidential  
 
 
 
Table 8.1 -1: Data Collection Schedule  
 
Procedure/Assessment  Study -Specific (iNod) 
or 
Standard of Care (SOC)   
Screening   
Baseline   
Procedure  Completion / 
Study Exit  
Informed consent form, including informed consent signature 
[CONTACT_827441]   X   
Demographics, including date of birth, and gender  iNod   X   
Physical Exam  iNod      
HCG Pregnancy Testing for women of childbearing potential  iNod   X   
Historic Diagnostic Chest CT  
Confirmed at enrollment, but per standard of care within 6 
weeks of procedure  SOC   
X    
Historic PET Results  SOC  O    
Medical history  iNod   X   
Sedation  SOC    X  
iNod System Diagnostic Procedure(s)  iNod    X  
iNod Ultrasound (US) Images including lesion visualization and 
needle visualized in the iNod US Field  iNod    X  
Fluoroscopic Images during iNod Maneuver(s)  iNod    O  
ROSE (Rapid on -site Evaluation) of obtained specimen (s)  SOC    X  
Complete Cytology of obtained specimen(s)  SOC    X X 
Standard of Care Diagnostic Procedures (as indicated as 
required)  SOC    O  
Standard of Care US Images including lesion visualization and 
needle visualized in the iNod US Field  SOC    X  
Fluoroscopic Images during Standard of Care Maneuver(s)  SOC    O  
ROSE (Rapid on -site Evaluation) of obtained specimen (s)  SOC    X  
Complete Cytology of obtained specimen(s)  SOC    X X 
Discharge X -ray SOC     X 
Device, Procedure, and Anesthesia -related adverse events 
assessment, including Day -[ADDRESS_1148061] -Procedure Call  iNod    X X 
 
 
 
 
 
Released  X = required; O = optional but recommended  
 
 
 
 
 
iNod Feasibility Clinical Protocol   
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 19 of 44  
91122035 AA.13  
 
 [LOCATION_011] Scientific Confidential. Unau thorized use is  prohibited.  Page 19 of 44  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 20 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 20 of 44   
  
 
8.2. Study Candidate  Screening  
 
Potential study candidates will be selected based on the investigator’s review of subject 
referrals for evaluation of their medical history and assessment of candidate’s Chest CT, 
completed within [ADDRESS_1148062] to 
the Informed Consent process. All subjects screened and consented will be patients of the 
inves tigator(s).  
 
8.3. Informed  Consent  
 
Written Informed Consent must be obtained for all subjects who are potential study 
candidates. Subjects will be asked to sign the Informed Consent form before any study - 
specific tests or procedures are performed. The Informe d Consent form is study -specific 
and must be approved by [CONTACT_282073] (IRB)/Ethics Committee 
(EC) and Competent Authority, as applicable.  
 
8.4. Baseline  
 
Must be conducted no more than 2 weeks before or on the day of (preceding) iNod 
System procedure.  
• Informed Consent  
• Eligibility Criteria  Assessment  
• Demographics  
• Bronchoscopy  History  
• Physical Exam including Height &  Weight  
• Confirmation of a peripheral pulmonary lesion, per historic Chest CT (within 6 
weeks of  precdure)  
 
Baseline attributes of the target lesion will be recorded:  
• Location of  Lesion  
• Size of  Lesion  
• Attributes of Lesion (e.g. solid or partial ground  glass)  
8.5. iNod Diagnostic  Procedure  
 
The subject will be prepared for the study procedure under sedation as per cur rent 
standard or care.  
The investigator will perform a bronchoscopic assessment of all lobes of the lung and 
confirm that there are no contraindications to continue with the iNod System procedure.  
Confidential  
[LOCATION_011]  Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148063] of this 
clinical study by [CONTACT_5756], free of charge. Each iNod System component will be 
utilized only to the extent and use limits, defined in the Investigator Brochure. Multiple (a 
minimum of 4) iNod Ultrasound Catheters and (a minimum of 4) iNod Biopsy Needles 
are to be available at the commencement of a study procedure.  
All iNod System components utilized during a procedure will be recorded, by [CONTACT_294133], to insure device accountability. The model number(s) of the bronchoscope(s) 
being utilized will also be captured.  
The following procedural data will be captured:  
• Timing of the total duration of the case, from initial introduction of the bronchoscope 
to final removal of  bronchoscope  
• Each iNod Maneuver will be timed from introduction of the iNod Biopsy Needle 
catheter, pre -loaded with the iNod Ultrasound Catheter, throu gh the removal of  the 
iNod Biopsy  Needle.  
• Intra -procedural Attributes of the target lesion(s) will be  recorded:  
o Location of target lesion (e.g., RB1, RB2, RB3, etc.) 
o Assessment of concentric lesion vs. eccentric  lesion  
o Assessment for positive bronchus  sign 
 
Imaging to be captured during the iNod System maneuvers, as identified with the serial 
number of the iNod Imaging System and iNod Biopsy Needle being utilized for each 
maneuver, will be collected as follows:  
 
• Ultrasound image of the target  lesion  
• Ultrasound image of the deployed iNod Biopsy Needle at the target  lesion  
• Supplemental fluoroscopic images, if collected, should also be retained and similarly 
associated to the specific maneuver by [CONTACT_827425] -site evaluation (ROSE) will be completed for all obtained specimens. Results 
will be associated with the serial number of the iNod Biopsy Needle being used for each 
unique specimen. ROSE interpretations, “adeq uate (for cytologic evaluation)” or 
“inadequate (for cytologic evaluation),” will be recorded. Collected specimens will 
undergo cytologic evaluation following the iNod procedure and final cytologic results 
will be reported in the study database.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 22 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 22 of 44   
  
 
The following situations would indicate the need to abandon the iNod System Procedure 
and proceed to salvage:  
• If the iNod System is unable to physically reach the lesion, as evidenced by [CONTACT_827426] . 
• If 3 separate aspi[INVESTIGATOR_827410] “inadequate (for cytologic evaluation),” the investigator should stop 
iNod maneuvers and proceed to salvage.  
 
8.6. Salvage  Procedure  
 
For study subjects for whom an adequate specimen, defined as a specimen that has been 
confirmed as suitable for cytologic evaluation, is not obtained from the iNod System 
diagnostic procedure but for whom continuation with endobronchial maneuvers are not 
contraindicated, additional standard of care (SOC) R -EBUS -guided diagnostic sampling 
maneuvers should be conducted.  
SOC R -EBUS -guided sampling maneuvers may be conducted utilizing various clinically 
standard sampling techniques, including but not limited to  fine-needle aspi[INVESTIGATOR_1516], 
brushings, or forceps. Similar to the iNod System procedure, accountability of all SOC 
devices utilized, timing, ultrasound image(s) of target lesion, fluoroscopic images of 
lesions and sampling device, as available, ROSE, and Fina l Cytology should be captured.  
 
8.7. Study  Completion  
 
Post-procedure, subjects will be followed through their discharge chest x -ray following 
their iNod System procedure.  
Verbal contact [CONTACT_827427] a member of the site study team 7 
(+/- 1) days post -procedure. The purpose of this call is for the study team to assess for 
any late -occurring study procedure -related or study device -related safety events.  
 
8.8. Source  Documents  
 
Where copi[INVESTIGATOR_827411] o f original electronic 
source documents are retained, these shall be signed and dated by a member of the 
investigation center team with a statement that it is a true reproduction of the original 
source document.  
Table 8.8 -1: Source Documentation Requirements  
 
Requirement  Disposition  
Historic Chest CT Report  Scanned de -identified file for upload in eCRF  
Evidence of Medical History that all Inclusionary 
and Exclusionary elements were confirmed at  Remain on -site 
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 23 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 23 of 44   
 Table 8.8 -1: Source Documentation Requirements  
 
Requirement  Disposition  
Baseline.   
Procedure Records  Remain on -site 
Procedure Worksheets inclusive of devices used 
per maneuver (by [CONTACT_827428]) and timing 
of each maneuver, both for iNod System and 
Standard of Care (as indicated) maneuvers  Remain on -site 
Cytology Report(s)  
• Rapid on -Site Evaluation (ROSE) results 
of each maneuver from which a 
specimen was obtained. Specimens must 
be documented & associated with the 
specific maneuver/specific device from 
which they were  obtained.  
• Final Cytology  Report(s)  Scanned de -identified file for upload in eCRF  
Operative Note(s)  Remain on -site 
Discharge X -Ray Report  Scanned de -identified file for upload in eCRF  
Procedure -related SAE Discharge Summaries  Scanned de -identified file for fax or email 
transmission the BSC Safety Trial Manager  
Abbreviations:  
 
9. Statistical  Considerations  
 
9.1. Endpoints  
 
9.1.1.  Primary  Endpoint  
 
Clinical success is defined as the iNod System’s ability to acquire adequate 
specimens of cellular matter suitable for the cytologic evaluation of targeted lung 
lesions, under real -time visualization. The rate of Clinical Success will be calculated 
as the number of peripheral pulmonary lesions for which adequate cytologic 
specimens suitable for cytologic evaluation were obtained divided by [CONTACT_827429].  
 
Hypotheses  
There will be no formal statistical hypothesis tested since this is an observational 
study documenting the first human use of the iNod System  
 
Sample Size  
Enrollment is capped at 30 subjects with a maximum of 10 subjects per center. Since 
no formal hypothe sis will be tested, there is no statistical justification of sample size.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 24 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 24 of 44   
 Peripheral pulmonary lesions vary in their location in the tracheobronchial tree. Their 
size, characteristics (e.g., concentric vs. eccentric), and a sample size  of 5-10 subjects 
per site allows greater potential to evaluate the usability and performance of the 
system for visualization and sampling this range of lesions.  
Performance feedback for this traditional feasibility study is sought from more than 1 
physici an. While staying within the sample size confines of a traditional feasibility 
study, [LOCATION_011] Scientific has elected to seek the expertise of 2 to 3 interventional 
bronchoscopi[INVESTIGATOR_11437].  
 
Statistical Methods  
Since no formal hypothesis is tested, only descriptive statistics will be used to 
summarize the primary endpoint.  
 
9.2. General Statistical  Methods  
9.2.1.  Analysis Sets  
Intent -to-Treat  Cohort  
The intent -to-treat (ITT) cohort consists of subjects enrolled in the study regardless of 
whether a specimen was obtained from the iNod System.  
 
Per Protocol Cohort  
The per -protocol (PP) cohort is a subset of the ITT subjects for whom a specimen was 
obtain ed using the iNod System.  
 
9.2.2.  Control of Systematic  Error/Bias  
 
All subjects who have met the inclusion/exclusion criteria and have signed the ICF 
will be eligible for enrollment in the study. Visual and/or electronic data review will 
be performed to identify  possible data discrepancies. Manual and/or automatic 
queries will be created in the EDC system and will be issued to the site for 
appropriate response. Site staff will be responsible for resolving all queries in the 
database  
 
9.2.3.  Number of Subjects per Invest igative  Site 
 
A maximum of 10 subjects can be enrolled at each investigative site.  
 
9.3. Data  Analyses  
 
Descriptive statistics will be presented for all ITT and PP subjects. The mean (± standard 
deviation) will be used to describe continuous variables with a normal distribution and 
the median (and interquartile range) will be used to describe continuous vari ables with a  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 25 of 44  
Released 91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 25 of 44   
 skewed distribution. Frequency tables will be used to summarize discrete variables. 
Proportions of subjects with adverse events and SAEs will be reported.  
 
9.3.1.  Interim  Analyses  
 
No formal interim analyses are planned for the purpose of stoppi[INVESTIGATOR_5690]. 
Informal interim analysis may be conducted for the purpose of submissions of 
abstracts to major professional meetings.  
 
9.3.2.  Subgroup  Analyses  
 
There are no planned subgroup an alyses.]  
 
9.3.3.  Justification of  Pooling  
 
The analyses will be presented using data pooled across centers as well as by [CONTACT_827430]. If deemed appropriate, stratified and multivariate analysis 
techniques, including Chi -square test or logistic regression will be used to assess 
differences between study centers to justify pooling data across centers.  
 
9.3.4.  Changes to Planned  Analyses  
 
Any changes to the planned statistical analyses will be documented in an amended 
Statistical Analysis Plan approved prior to performing the analysis. Cha nges from the 
planned statistical methods after performing the analysis will be documented in the 
clinical study report along with a reason for the deviation.  
 
10. Data  Management  
 
10.1. Data Collection, Processing, and  Review  
 
Subject data will be recorded in a limited access secure electronic data capture (EDC) 
system.  
The clinical database will reside on a production server hosted by [CONTACT_51580]. All changes 
made to the clinical data will be captured in an electronic audit trail and available for 
review by [CONTACT_5708] (BSC) or its representative. The associated 
RAVE software and database have been designed to meet regulatory compliance for 
deployment as part of a validated system compliant with laws and regulatio ns applicable 
to the conduct of clinical studies pertaining to the use of electronic records and 
signatures. Database backups are performed regularly.  
The Investigator provides his/her electronic signature [CONTACT_123374] (e CRFs) in compliance with local regulations. A written signature [CONTACT_827442] [CONTACT_1295]. Changes to  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 26 of 44  
Released 91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 26 of 44   
 data previously submitted to the sponsor require a new electronic signature [CONTACT_3265] [CONTACT_303440].  
Visual and/or electronic data review will be performed to identify possible data 
discrepancies. Manual and/or automatic  queries will be created in the EDC system and 
will be issued to the site for appropriate response. Site staff will be responsible for 
resolving all queries in the database.  
 
10.2. Data  Retention  
 
The Investigator or Investigational site will maintain, at the in vestigative site, in original 
format all essential study documents and source documentation that support the data 
collected on the study subjects in compliance with ICH/GCP guidelines. Documents must 
be retained for at least [ADDRESS_1148064]. These documents will be retained for a longer period of time by [CONTACT_827431]. It is BSC’s responsibility to 
inform the Investigator when these documents no longer need to be maintained. The 
Investigator will take measures to ensure that these essential documents are not 
accidentally damaged or destroyed. If for a ny reason the Investigator withdraws 
responsibility for maintaining these essential documents, custody must be transferred to 
an individual who will assume responsibility and BSC must receive written notification 
of this custodial  change.  
11. Amendments  
 
If a protocol revision is necessary which affects the rights, safety or welfare of the subject or 
scientific integrity of the data, an amendment is required. Appropriate approvals (e.g., 
IRB/EC/FDA/CA) of the revised protocol must be obtained prior to impl ementation.  
12. Deviations  
 
An Investigator must not make any changes or deviate from this protocol, except to protect 
the life and physical well -being of a subject in an emergency. An investigator shall notify the 
sponsor and the reviewing IRB/EC of any devia tion from the investigational plan to protect 
the life or physical well -being of a subject in an emergency, and those deviations which 
affect the scientific integrity of the clinical investigation. Such notice shall be given as soon 
as possible, but no lat er than [ADDRESS_1148065] be documented and rep orted to the sponsor using entry onto the eCRF. 
Sites may also be required to report deviations to the IRB/EC, per local guidelines and 
government regulations.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 27 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 27 of 44   
 Deviations will be reviewed and evaluated on an ongoing basis and, as necessary, appropriate 
corrective and preventive actions (including notification, center re -training, or 
discontinuation) will be put into place by [CONTACT_456].  
 
13. Device/Equipment  Account ability  
 
The investigational devices/equipment shall be securely maintained, controlled, and used 
only in this clinical study.  
The sponsor shall keep records to document the physical location of all investigational 
devices from shipment of investigational devices to the investigation sites until return or 
disposal.  
Records shall be kept by [CONTACT_827432]/equipment.  
The principal investigator [INVESTIGATOR_113611], use, return and disposal of the investigational devices/equipment, which shall include 
the following  
• Date of  receipt  
• Identification of each investigational dev ice/pi[INVESTIGATOR_502] (batch number or unique 
code)  
• Expi[INVESTIGATOR_5695], as  applicable  
• Date or dates of  use 
• Subject  identification  
• Date on which the investigational device/pi[INVESTIGATOR_5696]/explanted from 
subject, if  applicable  
• Date of return of unu sed, expi[INVESTIGATOR_5697], or malfunctioning investigational devices/equipment, if 
applicable.  
Written procedures may be required by [CONTACT_2091].  
 
14. Compliance  
 
14.1. Statement of  Compliance  
 
This study will be conducted in accordance with relevant sections of the International 
Standard (ISO) [ZIP_CODE]: Clinical Investigation of Medical devices for Human Subjects – 
Good Clinical Practice, the relevant parts of the ICH Guidelines for Good Clinical 
Practices, ethical principles that have their origins in the Declaration of Helsinki, and 
pertinent individual country laws and regulations. The study shall not begin until the  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 28 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 28 of 44   
 required approval/favorable opi[INVESTIGATOR_5698]/EC and/or regulatory authority has 
been obtained, if appropriate. Any additional requirements imposed by [CONTACT_1201]/EC or 
regulatory authority shall be followed, if appropriate.  
 
14.2. Investigator  Responsibilities  
 
The Principal Investigator [INVESTIGATOR_123318], the investigational 
plan/protocol, ISO [ZIP_CODE], ethical principles that have their origins in the  Declaration of 
Helsinki, any conditions of approval imposed by [CONTACT_3488]/EC, and prevailing 
local and/or country laws and/or regulations, whichever affords the greater protection to 
the subject.  
The Principal Investigator’s responsibilities includ e, but are not limited to, the following.  
• Prior to beginning the study, sign the Clinical Study Agreement and Protocol 
Signature [CONTACT_71660]/her agreement to conduct the study in accordance 
with the  protocol.  
• Provide his/her qualifications and exp erience to assume responsibility for the  proper 
conduct of the study and that of key members of the center team through up -to-date 
curriculum vitae or other relevant documentation and disclose potential conflicts of 
interest, including financial, that may interfere with the conduct of the clinical study 
or interpretation of  results.  
• Make no changes in or deviate from this protocol, except to protect the life and 
physical well -being of a subject in an emergency; document and explain any 
deviation from the approved protocol that occurred during the course of the  clinical 
investigation.  
• Create and maintain source documents throughout the clinical study and ensure  their 
availability with direct access during monitoring visits or audits; ensure that all 
clinical -investigation -related records are retained per  requirements.  
• Ensure the accurac y, completeness, legibility, and timeliness of the data reported to 
the sponsor in the CRFs and in all required  reports.  
• Record, report, and assess (seriousness and relationship to the  device/procedure) 
every adverse event and observed device  deficiency.  
• Report to BSC, per the protocol requirements, all SAEs and device deficiencies  that 
could have led to a  SADE.  
• Report to the IRB/EC and regulatory authorities any SAEs and device deficiencies 
that could have led to a SADE, if required by [CONTACT_827433]/EC, and supply BSC with any additional requested information related 
to the safety reporting of a particular  event.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 29 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 29 of 44   
 • Maintain the device accountability records and control of the device, ensuring that  the 
investigationa l device is used only by [CONTACT_113640]/designated users and in accordance 
with this protocol and instructions/directions for  use. 
• Allow the sponsor to perform monitoring and auditing activities, and be accessible to 
the monitor and respond to questions during  monitoring  visits.  
• Allow and support regulatory authorities and the IRB/EC when performing  auditing 
activities.  
• Ensure that informed consent is obtained in accordance with applicable laws, this 
protocol and local IRB/EC  requirements.  
• Provide adequate medical care to a subject during and after a subject’s participation 
in a clinical study in the case of adverse events, as described in the Informed Consent 
Form  (ICF).  
• Inform the subject of the nature and possible cause of any adverse eve nts 
experienced.  
• As applicable, provide the subject with necessary instructions on proper use, 
handling, storage, and return of the investigational device when it is used/operated  by 
[CONTACT_423].  
• Inform the subject of any new significant findings occurring  during the clinical 
investigation, including the need for additional medical care that may be  required.  
• Provide the subject with well -defined procedures for possible emergency situations 
related to the clinical study, and make the necessary arrangements f or emergency 
treatment, including decoding procedures for blinded/masked clinical investigations, 
as needed.  
• Ensure that clinical medical records are clearly marked to indicate that the subject is 
enrolled in this clinical  study.  
• Ensure that, if appropriat e, subjects enrolled in the clinical investigation are provided 
with some means of showing their participation in the clinical investigation, together 
with identification and compliance information for concomitant treatment measures 
(contact [CONTACT_827434]).  
• Inform, with the subject’s approval or when required by [CONTACT_2091], the 
subject’s personal physician about the subject’s participation in the clinical 
investigation.  
• Make all reasonable efforts to ascertain the reason(s) for a subject’s premature 
withdrawal from clinical investigation while fully respecting the subject’s  rights.  
• Ensure that an adequate investigation site team and facilities exist and are maintained 
and documented during the clinical  investigation.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page  30 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 30 of 44   
 • Ensure that maintenance and calibration of the equipment relevant for the  assessment 
of the clinical investigation is appropriately performed and documented, whe re 
applicable.  
 
14.2.1.  Delegation of  Responsibility  
 
When specific tasks are delegated by [CONTACT_2413], including but not limited to 
conducting the informed consent process, the investigator is responsible for 
providing appropriate training and adequat e supervision of those to whom tasks 
are delegated. The investigator is accountable for regulatory violations resulting 
from failure to adequately supervise the conduct of the clinical study.  
 
14.3. Institutional Review  Board  
 
Prior to gaining Approval -to-Enroll  status, the investigational center will provide to the 
sponsor documentation verifying that their IRB/EC is registered or that registration has 
been submitted to the appropriate agency, as applicable according to national/regulatory 
requirements.  
A copy o f the written IRB/EC and/or competent authority approval of the protocol (or 
permission to conduct the study) and Informed Consent Form, must be received by [CONTACT_272612]/e quipment. Prior approval must also be obtained for other materials related to 
subject recruitment or which will be provided to the subject.  
Annual IRB/EC approval and renewals will be obtained throughout the duration of the 
study as required by [CONTACT_5737]/country or IRB/EC requirements. Copi[INVESTIGATOR_5699]’s 
reports and the IRB/EC continuance of approval must be provided to the sponsor.  
 
14.4. Sponsor Responsibilities  
 
All information and data sent to BSC concerning subjects or their participation in this 
study will be considered confidential by [CONTACT_71640]. Only authorized BSC personnel or a BSC 
representative including Contract Research Organization (CRO ) will have access to these 
confidential records. Authorized regulatory personnel have the right to inspect and copy 
all records pertinent to this study. Study data collected during this study may be used by 
[CONTACT_113644], publication,  and to support future research and/or 
other business purposes. All data used in the analysis and reporting of this study will be 
without identifiable reference to specific subject name.  
[LOCATION_011] Scientific will keep subjects’ health information confidential  in accordance with 
all applicable laws and regulations. [LOCATION_011] Scientific may use subjects’ health 
information to conduct this research, as well as for additional purposes, such as 
overseeing and improving the performance of its device, new medical resear ch and 
proposals for developi[INVESTIGATOR_71613], and other business 
purposes. Information received during the study will not be used to market to subjects;  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148066] names will not be placed on any mailing lists or sold to anyone for marketing 
purposes.  
 
14.4.1.  Role of [LOCATION_011] Scientific  Representatives  
 
[LOCATION_011] Scientific personnel can provide technical support to the investigator 
and other health care personnel (colle ctively HCP) as needed during the iNod 
System procedure required by [CONTACT_760]. Support may include HCP 
training, addressing HCP questions, or providing clarifications to HCPs 
concerning the operation of BSC equipment/devices.  
In addition, BSC personnel may perform certain activities to ensure study 
quality. These activities may include the following.  
• Observing testing or medical procedures to provide information relevant 
to protocol  compliance  
• Reviewing collected data and study documentation for completeness and 
accuracy  
[LOCATION_011] Scientific personnel will not do the following.  
• Practice  medicine  
• Provide medical diagnosis or treatment to  subjects  
• Discuss a subject’s condition or treatment with a sub ject without the 
approval and presence of the  HCP  
• Independently collect critical study data (defined as primary or  secondary 
endpoint  data)  
• Enter data in electronic data capture systems or on paper case  report 
forms  
 
14.5. Insurance  
 
Where required by [CONTACT_5737]/country regulation, proof and type of insurance coverage, by 
[CONTACT_71649].  
 
15. Monitoring  
 
Monitoring will be performed during the study to assess continued compliance with the 
protocol and applicable regulations. In addition, the monitor verifies that study records are 
adequately maintained, that data are reported in a satisfactory manner with respect to 
timeliness, adequacy, and accuracy, and that the Investigator continues to have sufficient 
staff and facilities to conduct the study safely and effectively. The Investigator/institution 
guarantees direct access to original source documents by [CONTACT_5739] C personnel, their designees, and 
appropriate regulatory  authorities.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148067] to a quality assurance audit by [CONTACT_5742], as well as 
inspection by [CONTACT_4708]. It is important that the Investigator and 
relevant study personnel are available during on -site monitoring visits or audits and that 
sufficient time is devoted to the process.  
 
16. Potential Risks and  Benefits  
 
16.1. Anticipated Device -related & Procedure -related Adverse  Events  
 
The following anticipated adverse events (AE) have been identified with the diagnostic 
procedure that is being studied. Anticipated Adverse Events related specifically to the device 
(iNod System) as well as similar standard of care procedural devices are ide ntified with an 
asterisk (*).  
 
• Allergic Reaction to  Medication  
• Aspi[INVESTIGATOR_1516]  
• Bleeding*  
• Bronchospasm  
• Cardiac Arrhythmia or  Arrest  
• Cough  
• Dyspnea  
• Fever  
• Infection  
• Hemomediastinum*  
• Hemorrhage*  
• Hypotension  
• Infection*  
• Inflammation*  
• Laceration*  
• Laryngospasm  
• Nausea  
• Nerve  Damage  
• Over sedation leading  to: 
o Hypercapnia  
o Hypoxemia  
o Hypotension  
• Pain 
• Perforation*  
• Post-Procedural Chest  Pain 
• Post-Procedural  Hiccup  
• Pneumonia  
• Pneumoperitoneum*  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 33 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 33 of 44   
 • Pneumothorax  * 
• Pneumomediastinum*  
• Respi[INVESTIGATOR_827412]  
• Tissue  Damage*  
• Tumor  Seeding  
• Transient Lowered  Oxygen  
• Vomiting  
 
16.2. Risks Associated with the Study  Device(s)  
 
No incremental risks are associated with the study device that are above those of market 
available products.  
 
16.3. Risks associated with Participation in the Cli nical  Study  
 
Participation in the trial may result in a prolonged procedure when compared to standard 
of care sampling of peripheral pulmonarylesions.  
Pariticipation in the trial may result in an unintended breach of the subject’s 
confidentiality.  
 
16.4. Risk Minimization  Actions  
 
Additional risks may exist. Risks can be minimized through compliance with this 
protocol, performing procedures in the appropriate hospi[INVESTIGATOR_84365], adherence to 
subject selection criteria, close monitoring of the subject's physiologic status during 
research procedures and/or follow -ups and by [CONTACT_827435].  
 
16.5. Anticipated  Benefits  
 
Subjects may not receive any benefit from being in this study. However, medical science 
and future subjects m ay benefit from this study.  
 
16.6. Risk to Benefit  Rationale  
 
Based on collected reports in literature to -date, the risk -to-benefit ratio is within reason 
for foreseeable risks. However, literature reports do not always capture all side effects. 
Observation and follow -up of subjects is required as outlined in the protocol.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 34 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 34 of 44   
 17. Safety  Reporting  
 
17.1. Reportable Events by [CONTACT_827436]:  
• All Serious Adverse  Events  
• All Study Device, Study Procedure, and Study Procedure Anesthesia -related Adverse 
Events  
• All Investig ational Device  Deficiencies  
• Unanticipated Adverse Device  Effects  
• New findings/updates in relation to already reported  events  
When possible, the medical diagnosis should be reported as the Event Term instead of 
individual symptoms.  
If it is unclear whether or not an event fits one of the above categories, or if the event 
cannot be isolated from the device, procedure, or anesthesia, it should be submitted as an 
adverse event and/or device deficiency.  
Any AE event required by [CONTACT_760], experienced by [CONTACT_941] s tudy subject after informed 
consent and once considered enrolled in the study (as defined in study subject 
classification section), whether during or subsequent to the procedure, must be recorded 
in the eCRF.  
Underlying diseases are not reported as AEs unless there is an increase in severity of 
frequency during the course of the investigation. Death should not be recorded as an AE, 
but should only be reflected as an outcome of one (1) specific SAE (see Table 17 .2-1 for 
AE definitions).  
Refer to Section 16 for the known risks associated with the study device(s).  
Adverse event definitions are provid ed in Table 17.1 -1. Administrative edits were made 
to combine definitions from ISO 141 55-2011 and MEDDEV 2.7/3 12/2010.  
 
Table 17.1 -1: Safety Reporting Definitions  
 
Term  Definition  
Adverse Event (AE)  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 12/[ADDRESS_1148068] clinical signs (including an abnormal laboratory finding) in 
subjects, users or other persons, whether or not related to the investigational 
medical device.  
NOTE 1: This include s events related to the investigational medical device 
or comparator.  
NOTE 2: This definition includes events related to the procedures involved 
(any procedure in the clinical investigation plan).  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 35 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 35 of 44   
 Table 17.1 -1: Safety Reporting Definitions  
 
Term  Definition  
 NOTE 3: For users or other persons, this definition is restricted to events 
related to the investigational medical device.  
Adverse Device Effect (ADE)  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 12/2010  Adverse event related to the use of an investigational medical device  
NOTE 1: This definition includes any adverse event resulting from 
insufficient or inadequate instructions for use, the deployment, the 
implantation, the installation, the operation, or a ny malfunction of the 
investigational medical device.  
NOTE 2: This definition includes any event resulting from use error or 
from intentional misuse of the investigational medical device.  
Serious Adverse Event (SAE)  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 12/2010  Adverse event that:  
• Led to  death,  
• Led to serious deterioration in the health of the subject, that either 
resulted  in: 
o a life -threatening illness or injury,  or 
o a permanent impairment of a body structure or a body function,  or 
o in-patient or prolonged hospi[INVESTIGATOR_272563],  or 
o medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body  function  
 
• Led to fetal distress, fetal death, or a congenital abnormality or  birth 
defect.  
NOTE 1 : Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure required by [CONTACT_5745], without serious 
deterioration in health, is not considered a serious adverse event.  
Serious Adverse Device Effect 
(SADE)  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 12/[ADDRESS_1148069] (UADE)  
 
Ref: 21 CFR Part 812  
 
Note : For US IDE studies only, 
otherwise remove UADE from 
table  Any serious adverse effect on health or safety or any life -threatening 
problem or death caused by, or associated with, a device, if that effect, 
problem, or death was not  previously identified in nature, severity, or degree 
of incidence in the investigational plan or application (including a 
supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, s afety, or welfare 
of subjects.  
Device Deficiency  
 
Ref: ISO [ZIP_CODE] -2011  
 
Ref: MEDDEV 2.7/3 12/[ADDRESS_1148070] to its 
identity, quality, durability, reliability, safety or performance.  
NOTE 1 : Device deficiencies include malfunctions, misuse or use errors, 
and inadequate labeling.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 36 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 36 of 44   
 Table 17.1 -1: Safety Reporting Definitions  
 
Term  Definition  
  
Abbreviations: EC=Ethics Committee; IRB=Institutional Review Board  
 
Underlying diseases are not reported as AEs unless there is an increase in severity or 
frequency during the course of the investigation. Death should not be recorded as an AE, 
but should only be reflected as an outcome of a specific SAE (see  Table 17.1 -1 for AE 
definitions).  
Any related AE experienced by [CONTACT_307969], whether during 
or subsequent to the procedure, must be recorded in the eCRF.  
Refer to Sec tion 16  for the known risks associated with the study device(s).  
 
17.2. Relationship to Study  Device(s)  
 
The Investigator must assess the relationship of the AE to the study device, study 
procedure, or study procedure anesthesia as related or not related. See criteria in Table  
17.2-1: 
 
 
Table 17.2 -1: Criteria for Assessing Relationship of Study Device, Study Procedure, & 
Study Procedure Anesthesia to Adverse Event  
 
Classification  Description  
Not Related  The adverse event is determined to be due to a concurrent illness or effect of another 
device/drug and is not related to the investigational product.  
Related  • The adverse  event  is determined  to be potentially  related  to the investigational 
product, and an alternative etiology is equally or less likely compared to the 
potential relationship to investigational product,  or 
• There is a strong relationship to investigational product, or recurs on re -challenge, 
and another etiology is unlikely,  or 
• There is no other reasonable medical explanation for the  event.  
 
17.3. Investigator Reporting  Requirements  
 
The communication requirements for reporting to BSC are as show n in Table 17.3 -1. 
Table 17.3 -1: Investigator Reporting Requirements  
 
Event Classification  Communication Method  Communication Timeline  
Unanticipated Adverse Device 
Effect  Complete AE eCRF page with all 
available new and updated information.  • Within [ADDRESS_1148071] 
becoming aware of the  event.  
• Terminating at the end of the 
study  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 37 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 37 of 44   
 Table 17.3 -1: Investigator Reporting Requirements  
 
Event Classification  Communication Method  Communication Timeline  
Serious Adverse Event 
including Serious Adverse 
Device Effects  Complete AE eCRF page with all 
available new and updated information.  • Within [ADDRESS_1148072] 
becoming aware of the event or 
as per local/regional  regulations.  
• Reporting required throug h the 
end of the  study  
Provide all relevant source 
documentation (unidentified) for 
reported event  • When documentation is 
available  
Device Deficiencies (including 
but not limited to failures, 
malfunctions, and product 
nonconformities)  
Note: Any Investigational 
Device Deficiency that might 
have led to a serious adverse 
event if a) suitable action had 
not been taken or b) 
intervention had not been 
made or c) if circumstances 
had been less fortunate is 
considered a reportable event.  Comple te Device Event Form  • Within [ADDRESS_1148073] 
becoming aware of the event and 
as per local/regional  regulations.  
• Reporting required through the 
end of the  study  
Adverse Event  Complete AE eCRF page, which 
contains such information as date of 
AE, treatment of AE resolution, 
assessment of seriousness and 
relationship to the device.  • In a timely manner (e.g. 
Recommend within 10 business 
days) after becoming aware of 
the information  
• Reporting required through the 
end of the  study  
Abbreviations: AE=adverse event; CRF=case report form; IDE=Investigational Device Exemption; 
UADE=unanticipated adverse device effect  
 
 
17.4. [LOCATION_011] Scientific Device  Deficiencies  
 
All device deficiencies (including but not limited to failures, malfunctions, use errors, 
product nonconformities, and labeling errors) will be documented and reported to BSC.  If 
possible, the device(s) should be returned to BSC for analysis. Instructions for returning 
the investigational device(s) will be provided. If it is not possible to return the device, the 
investigator should document why the device was not returned and the final disposition 
of the device. Device failures and malfunctions should also  be documented in the 
subject’s medical  record.  
Device deficiencies (including but not limited to failures, malfunctions, and product 
nonconformities) are to be reported as Device Events and are not to be reported as  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148074] led to a serious adverse event if a) 
suitable action had not been taken or b) intervention had not been made or c) if 
circumstances had been less fortunate is considered a reportable event.  
 
17.5. Reporting t o Regulatory Authorities / IRBs / ECs /  Investigators  
 
BSC is responsible for reporting adverse event information to all participating 
investigators and regulatory authorities, as applicable.  
The Principal Investigator [INVESTIGATOR_5703]/ EC, and regulatory 
authorities of UADE and SAE as required by [CONTACT_5737]/regional regulations.  
 
18. Informed  Consent  
 
Subject participation in this clinical study is voluntary. Informed Consent is required from all 
subjects or their legally authorized representativ e. The Investigator is responsible for 
ensuring that Informed Consent is obtained prior to the use of any investigational devices, 
study -required procedures and/or testing, or data collection.  
The obtaining and documentation of Informed Consent must be in accordance with the 
principles of the Declaration of Helsinki, ISO [ZIP_CODE], any applicable national regulations, and 
local Ethics Committee and/or Regulatory authority body, as applicable. The ICF must be 
approved by [CONTACT_113653]’s delegate (e.g. CRO), the cent er’s IRB/EC, or central IRB, if 
applicable.  
[LOCATION_011] Scientific will provide a study -specific template of the ICF to investigators 
participating in this study. The ICF template may be modified to meet the requirements of the 
investigative center’s IRB/EC. An y modification requires approval from BSC prior to use of 
the form. The ICF must be in a language understandable to the subject and if needed, BSC 
will assist the center in obtaining a written consent translation. Translated consent forms 
must also have IR B/EC approval prior to their use. Privacy language shall be included in the 
body of the form or as a separate form as  applicable.  
The process of obtaining Informed Consent shall at a minimum include the following steps, 
as well as any other steps required by [CONTACT_5751], rules, regulations and guidelines:  
• be conducted by [CONTACT_079] [INVESTIGATOR_827413],  
• include a description of all aspects of the clinical study that are relevant to the  subject’s 
decision to participate throughout the clinical  study,  
• avoid any coercion of or undue influence of subjects to  participate,  
• not waive or appear to waive subject’s legal  rights,  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 39 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 39 of 44   
 • use native language that is non -technical and understandable to the subject or his/her 
legal  representative,  
• provide ample time for the subject to consider participation and ask questions if 
necessary,  
• ensure important new information is provided to new an d existing subjects throughout  the 
clinical  study.  
The ICF shall always be signed and personally dated by [CONTACT_71656], rules, regulations and guidelines and by 
[CONTACT_1755] /or an authorized designee responsible for conducting the informed 
consent process. If a legal representative signs, the subject shall be asked to provide informed 
consent for continued participation as soon as his/her medical condition allows. The origina l 
signed ICF will be retained by [CONTACT_71657] a copy of the signed and dated document and 
any other written information must be given to the person signing the form.  
Failure to obtain subject consent will be reported by [CONTACT_827437] b ody 
according to their requirements (e.g., FDA requirement is within 5 working days of learning 
of such an event). Any violations of the informed consent process must be reported as 
deviations to the sponsor and local regulatory authorities (e.g. IRB/EC), as appropriate.  
If new information becomes available that can significantly affect a subject's future health 
and medical care, that information shall be provided to the affected subject(s) in written form 
via a revised ICF or, in some situations, enrolled subjects may be requested to sign and date 
an addendum to the ICF. In addition to new significant information during the course of a 
study, other situations may necessitate revision of the ICF, such as if there are amendments 
to the applicable laws, protoc ol, a change in Principal Investigator, administrative changes, or 
following annual review by [CONTACT_1201]/EC. The new version of the ICF must be approved by 
[CONTACT_1201]/EC. [LOCATION_011] Scientific approval is required if changes to the revised ICF are 
requested by [CONTACT_941] c enter’s IRB/EC. The IRB/EC will determine the subject population to  be 
re-consented.  
 
19. Safety Monitoring  Process  
 
To promote early detection of safety issues, the BSC Medical Monitor will provide 
evaluations of safety events. Success of this program requires dynamic collection of 
unmonitored data as soon as the event is reported. This is expedited through BSC’s Global  
Safety Office, which is responsible for coordinating the collection of information for the 
subject dossier from the centers and core laboratories. During regularly scheduled monitoring 
visits, clinical research monitors will support the dynamic reporting process through their 
review of source document information.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 40 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 40 of 44   
 20. Suspension or  Termination  
 
20.1. Premature Termination of the  Study  
 
[LOCATION_011] Scientific Corporation reserves the right to terminate the study at any stage but 
intends t o exercise this right only for valid scientific or administrative reasons and 
reasons related to protection of subjects. Investigators, associated IRBs/ECs, and 
regulatory authorities, as applicable, will be notified in writing in the event of study 
termin ation.  
 
20.1.1.  Criteria for Premature Termination of the  Study  
 
Possible reasons for premature study termination include, but are not limited to, the 
following.  
o The occurrence of unanticipated adverse device effects that present a 
significant or unreasonable risk  to subjects enrolled in the  study.  
o An enrollment rate far below expectation that prejudices the conclusion of  the 
study.  
o A decision on the part of [LOCATION_011] Scientific to suspend or discontinue 
development of the  device.  
 
20.2. Termination of Study Participation by [CONTACT_5717]/ EC 
Approval  
 
Any investigator or IRB in the iNod Feasibility Study may discontinue participation in 
the study or withdrawal approval of the study, respectively, with suitable writt en notice to 
[LOCATION_011] Scientific. Investigators, associated IRBs, and regulatory authorities, as 
applicable, will be notified in writing in the event of these  occurrences.  
 
20.[ADDRESS_1148075]  Follow -up 
 
In the event of premature study  termination a written statement as to why the premature 
termination has occurred will be provided to all participating centers by [CONTACT_827438]. The IRB/EC and regulatory authorities, as applicable, will be notified.  
Detailed information on how enroll ed subjects will be managed thereafter will be 
provided.  
In the event an IRB terminates participation in the study, participating investigators, 
associated IRBs/ECs, and regulatory authorities, as applicable, will be notified in writing. 
Detailed informati on on how enrolled subjects will be managed thereafter will be 
provided by [CONTACT_5756].  
In the event an investigator terminates participation in the study, study responsibility will 
be transferred to a co -investigator, if possible. In the event there  are no opportunities to  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 41 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 41 of 44   
 transfer investigator responsibility; detailed information on how enrolled subjects will be 
managed thereafter will be provided by [CONTACT_5756].  
The investigator must return all documents and investigational product to [LOCATION_011] 
Scientific, unless this action would jeopardize the rights, safety, or welfare of the 
subjects.  
 
20.4 Criteria for Suspending/Terminating a Study  Center  
 
[LOCATION_011] Scientific Corporat ion reserves the right to stop the inclusion of subjects at a 
study center at any time after the study initiation visit if no subjects have been enrolled 
for a period beyond 3months after center initiation, or if the center has multiple or severe 
protocol violations/noncompliance without justification and/or fails to follow remedial 
actions.  
In the event of termination of investigator participation, all study devices and testing 
equipment, as applicable, will be returned to BSC unless this action would jeop ardize the 
rights, safety or well -being of the subjects. The IRB/EC and regulatory authorities, as 
applicable, will be notified. All subjects enrolled in the study at the center will continue 
to be followed through resolution of any procedure -related adver se events unled they are 
considered to endure in a chronic nature. The Principal Investigator [INVESTIGATOR_153580] -up visits unless BSC notifies the investigational center 
otherwise.  
 
21. Publication  Policy  
 
In accordance with the  Corporate Policy on the Conduct of Human Subject Research, BSC 
requires disclosure of its involvement as a sponsor or financial supporter in any publication 
or presentation relating to a BSC study or its results. In accordance with the Corporate Policy 
for the Conduct of Human Subject Research, BSC will submit study results for publication 
(regardless of study outcome) following the conclusion or termination of the study. [LOCATION_011] 
Scientific Corporation adheres to the Contributorship Criteria set forth in th e Uniform 
Requirements of the International Committee of Medical Journal Editors (ICMJE; 
http://www.icmje.org). In order to ensure the public disclosure of study results in a timely 
manner, while maintaining an unbiased presentation of study outcomes, BSC personnel may 
assist authors and investigators in publication preparation provided the following guidelines 
are followed.  
1. All authorship and contributorship requirements as described above must  be 
followed.  
2. BSC involvement in the publication preparation an d the BSC Publication Policy 
should be discussed with the Coordinating Principal Investigator(s) and/or 
Executive/Steering Committee at the onset of the  project.  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page [ADDRESS_1148076] and Senior authors are the primary drivers of decisions  regarding 
publication content, review, approval, and  submission.  
 
22. Bibliography  
 
 
1. World Health Organization. International Agency for Research on Cancer. 
GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevelence 
Worldiwde in 2012. Lung Cancer. Acc essed November 10,  2014.  
2. Centers for Disease Control and Prevention. National Center for Health Statistics. 
CDC WONDER On -line database, compi[INVESTIGATOR_827414] 1999 - 
2012 Series 20 No. 2R,  2014.  
3. U.S. Nation Institues of Health. National C ancer Institute. SEER Cnacer Statistics 
Review,  1975 -2011.  
4. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with  pulmonary 
nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: 
American College of Chest Physicia ns evidence -based clinical practice guidelines. 
Chest 2013;  143:e93S -120S.  
5. Aberle DR, Adams AM, Berg CD, et al. Reduced lung -cancer mortality with low - 
dose computed tomographic screening. The New England journal of medicine 2011; 
365:395 -409. 
6. Wahidi MM, G overt JA, Goudar RK, et al. Evidence for the treatment of patients 
with pulmonary nodules: when is it lung cancer?: ACCP evidence -based clinical 
practice guidelines (2nd edition). Chest 2007;  132:94S -107S.  
7. Gaeta M, Pandolfo I, Volta S, et al. Bronchus sign  on CT in peripheral carcinoma  of 
the lung: value in predicting results of transbronchial biopsy. AJR Am J Roentgenol 
1991;  157:1181 -1185.  
8. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: 
Diagnosis and management of lung cancer, 3rd ed: American College of Chest 
Physicians evidence -based clinical practice guidelines. Chest 2013;  143:e142S -165S.  
9. Eberhardt R, Morgan RK , Ernst A, Beyer T, Herth FJF. Comparison of suction 
catheter versus forceps biopsy for sampling of solitary pulmonary nodules guided by 
[CONTACT_827439]. Respi[INVESTIGATOR_1516]  2010;79(1):[ADDRESS_1148077]  2012;142(2):385 -393. 
11. Goldstein RA, et al. Clinical role of bronchoalveolar lavage in adults with  pulmonary 
disease. Am Rev Resp ir Dis. 1990  Aug;142(2):481 -6. 
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 43 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 43 of 44   
  
 
23. Abbreviations and Definitions  
23.1 Abbreviations  
Abbreviations are shown in table 23.1 -1. 
 
 
Table 23.1 -1: Abbreviations  
Acronym  Definition  
ADE  Adverse Device  Effect  
AE Adverse  Event  
CT Computed  Tomography  
CXR  Chest  X-Ray 
DFU  Directions for  Use 
EBB  Endobronchial  Biopsy  
EBUS  Endobronchial  Ultrasound  
eCRF  Electronic Case Report  Form  
EC Ethics  Committe  
EDC  Electronic Data  Capture  
FB Flexible  Bronchoscopy  
FDA  Food and Drug  Administration  
GCP  Good Clinical  Practices  
IB Investigator  Brochure  
ICF Informed Consent Form  
ICH International Conference on  Harmonization  
IRB Institutonal Review  Board  
ISO 
ITT International Standards Organization 
Intent -to-Treat  
MDU  Motor Drive  Unit 
PP Per-Protocol  
PZT Pi[INVESTIGATOR_827415]  
R-EBUS  Radial Endobronchial  Ultrasound  
ROSE  Rapid On -Site Evaluation  
SADE  Serious Adverse Device  Effect  
SAE  Serious Adverse  Event  
TBLB  Transbronchial Lung  Biopsy  
TBNA  Transbronchial Needle  Aspi[INVESTIGATOR_827416] -Assisted Thorascopic  Surgery  
VB Virtual  Bronchoscopy  
Confidential  
[LOCATION_011] Scientific 
iNod Feasibility Clinical Protocol  
91122035 Rev/Ver AA  
Page 44 of 44  
Released  91122035 AA.13  iNod Feasibility Clinical Protocol  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited. Page 44 of 44   
 23.2.  Definitions  
 
Terms are def ined in Table 23.2 -1. 
Table 23.2 -1: Definitions  
Term  Definition  
 
 
SOURCE  DATA  All information in original records and certified copi[INVESTIGATOR_827417],  observations,  or other  activities  in a clinical  trial necessary  for 
the reconstruction and evaluation of the trial. Source data are contained in the 
source documents (original records or certified  copi[INVESTIGATOR_014]).  
SOURCE  DOCUMENTS  Original documents, data, and records. 
Abbreviations are defined in Table  23.1-1. 